Risks from antipsychotic medications in children and adolescents [1]

JAMA

Volumn 303, Issue 8, 2010, Pages 729-

  Mangurian, Christina ^a   Fuentes Afflick, Elena ^b   Newcomer, John W ^c  

^a Department of Psychiatry ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE;

BODY COMPOSITION; BODY MASS; BODY WEIGHT; ENVIRONMENTAL FACTOR; ETHNICITY; HEREDITY; HUMAN; LETTER; LIPID BLOOD LEVEL; OBESITY; PRIORITY JOURNAL; RACE DIFFERENCE; SIDE EFFECT; WEIGHT GAIN; ADOLESCENT; COHORT ANALYSIS; DRUG EFFECT; EPIDEMIOLOGY; ETHNIC GROUP; LIPID METABOLISM; NOTE; RACE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; HUMANS; LIPID METABOLISM; SELECTION BIAS; WEIGHT GAIN;

EID: 77249105962     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.131     Document Type: Letter

References (3)

1. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during firsttime use in children and adolescents. JAMA. 2009;302(16):1765-1773.
2. Ader M, Garvey WT, Phillips LS, et al. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J Psychiatr Res. 2008;42(13):1076-1085.
3. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009;110(1-3):95- 102.